Scarica l'app Stockscreener
5.7642
3.43%
-0.1858
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$5.95
Aprire:
$5.62
Volume 24 ore:
12.53M
Relative Volume:
0.47
Capitalizzazione di mercato:
$2.30B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.7188
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
-11.46%
1M Prestazione:
+12.01%
6M Prestazione:
-20.64%
1 anno Prestazione:
-21.72%
Intervallo 1D:
$5.575
$5.82
Intervallo di 1 settimana:
$5.575
$6.685
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.76 | 2.52B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.96 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.54 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.62 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
676.74 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.01 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
What are the latest earnings results for Recursion Pharmaceuticals Inc.Pre Market Review For Consistent Profits - jammulinksnews.com
When is Recursion Pharmaceuticals Inc. stock expected to show significant growthFinancial News Outlook For 2025 - jammulinksnews.com
What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Financial News Data Feed With Proven Results - jammulinksnews.com
What is the risk reward ratio of investing in Recursion Pharmaceuticals Inc. stockSwing Trade Growth Plan With High Returns - jammulinksnews.com
How does Recursion Pharmaceuticals Inc. generate profit in a changing economyBreakout Stocks Ideas For 2025 - jammulinksnews.com
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034 - GlobeNewswire Inc.
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. - AOL.com
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion's Q2 2025 Earnings: A TechBio Powerhouse Poised for Breakthroughs and Synergy-Driven Growth - AInvest
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th - The Globe and Mail
Short Covering May Lift Recursion Pharmaceuticals Inc. in Near TermWeekly Growth Stock Entry Point Alerts Highlighted - metal.it
Why Recursion Pharmaceuticals Stock Got Mashed on Monday - AOL.com
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - MSN
Recursion Pharmaceuticals Inc. Approaches Psychological Resistance LevelBreakout Entry Signal Confirmation Tool Used - metal.it
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better? - 24/7 Wall St.
What institutional investors are buying Recursion Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
What is the dividend policy of Recursion Pharmaceuticals Inc. stockMaximize gains with timely market signals - jammulinksnews.com
How volatile is Recursion Pharmaceuticals Inc. stock compared to the marketUnlock powerful stock screening techniques - jammulinksnews.com
Palantir, Nvidia & Tempus AI: The Future of Medicine in 2025 - AInvest
Big Pharma's Disruption: AI-Powered Palantir, Tempus, and Recursion Change the Game - AInvest
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills - Benzinga
RXRX Stock Surges: What Awaits Next? - timothysykes.com
Recursion Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma - Benzinga
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance
Is Recursion Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - PrintWeekIndia
What drives Recursion Pharmaceuticals Inc. stock priceStrongest growth potential - Autocar Professional
How high can Recursion Pharmaceuticals Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? - MSN
What analysts say about Recursion Pharmaceuticals Inc. stockSignificant capital appreciation - PrintWeekIndia
RXRX September 5th Options Begin Trading - Nasdaq
Recursion Pharmaceuticals Experiences 10.7% Stock Price Surge Amid Strong Investor Interest - AInvest
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? - The Globe and Mail
Recursion Pharmaceuticals Trading Volume Drops 52.75% to $23.7 Million, Ranks 464th in Market - AInvest
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism - FinancialContent
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
0.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):